Supernus Pharmaceuticals, Inc. (SUPN)

51.93 +0.22 (+0.43%) USD  |  NASDAQ  |  Dec 24, 12:34
More

Supernus Pharmaceuticals SG&A Expense (TTM): 442.58M for Sept. 30, 2025

SG&A Expense (TTM) Chart

View SG&A Expense (TTM) for SUPN.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (TTM) Chart
Start Trial

Historical Data

View Historical Data
Start Trial

SG&A Expense (TTM) Range, Past 5 Years

View SG&A Expense (TTM) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (TTM) Benchmarks

View SG&A Expense (TTM) Benchmarks
Start Trial
BridgeBio Pharma, Inc. 467.92M
The Cooper Cos., Inc. 1.628B
Assembly Biosciences, Inc. 18.80M
Amphastar Pharmaceuticals, Inc. 126.42M
Viking Therapeutics, Inc. 52.36M